

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-26) UBAMATAMAB
 PRONUNCIATION ue" ba mat' a mab
 THERAPEUTIC CLAIM Treatment of ovarian cancer

CHEMICAL NAMES

1. Immunoglobulin G4 [232-proline,237-proline,238-valine,239-alanine,de-240-glycine,439-arginine,440-phenylalanine,449-proline], anti-(human CD3 antigen ε-chain) (human monoclonal REGN4018 γ4-chain), disulfide with human monoclonal REGN4018 κ-chain, (230→223'),(233→226')-bis(disulfide) with immunoglobulin G4 [225-proline,230-proline,231-valine,232-alanine,de-233-glycine] anti-(human cancer-associated antigen CA-125) (human monoclonal REGN4018 γ4-chain) disulfide with human monoclonal REGN4018 κ-chain
2. immunoglobulin G4-kappa bispecific: anti-(*Homo sapiens* T-cell surface glycoprotein CD3 epsilon chain (T-cell surface antigen T3/Leu-4 epsilon chain, CD3e antigen)) and anti-(*Homo sapiens* Mucin-16 (ovarian cancer-related tumor marker CA125, Ovarian carcinoma antigen CA125)); human monoclonal antibody; γ4 heavy chain anti CD3 antigen(1-450) [*Homo sapiens* VH (IGHV3-9*01 (98%) –(IGHD)-IGHJ1*01 (91%)) [8.8.17] (1-124) -*Homo sapiens* IGHG4*01 {hinge[S¹⁰>P(232)], CH2[E³>P(237),F⁴>V(238), L⁵>del,G⁶>A(239)], CH3[H⁹⁵>R(438),Y⁹⁶>F(439),L¹⁰⁵>P(448)]} (125-450)] (138-215')-disulfide with κ light chain (1'-215') [*Homo sapiens* V-KAPPA (*Homo sapiens* IGKV1-39*01 (98%) –IGKJ5*01)[6.3.10] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; (230-223":233-226")-bisdisulfide with γ4 heavy chain anti CA125 antigen(1"-443") [*Homo sapiens* VH (IGHV3-11*01 (89%) –(IGHD)-IGHJ5*01) [8.8.10] (1"-117") -*Homo sapiens* IGHG4*01 {hinge[S¹⁰>P(225")], CH2[E³>P(230"), F⁴>V(231"),L⁵>del,G⁶>A(232")]} (118"-443")] (131"-215'")-disulfide with κ light chain (1'"-215'") [*Homo sapiens* V-KAPPA (*Homo sapiens* IGKV1-39*01 (98%) –IGKJ5*01)[6.3.10] (1'"-108'") -*Homo sapiens* IGKC*01 (109'"-215'")]

STRUCTURAL FORMULA

Heavy chain X

EVQLVESGGG	LVQPGRSLRL	SCAASGFTFD	DYSMHVWRQA	PGKGLEWVSG	50
ISWNSGSKGY	ADSVKGRFTI	SRDNAKNSLY	LQMNSLRAED	TALYYCAKYG	100
SGYGKFYHYG	LDVWGQGTTV	TVSSASTKGP	SVFPLAPCSR	STSESTAALG	150
CLVKDYFPEP	VTVSWNSGAL	TSGVHTFPAV	LQSSGLYSLS	SVVTVPSSSL	200
GTKTYTCNVD	HKPSNTKVDK	RVESKYGPPC	PPCPAPPVAG	PSVFLFPPKP	250
KDTLMISRTP	EVTCVVVDVS	QEDPEVQFNW	YVDGVEVHNA	KTKPREEQFN	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKG	LPSSIEKTIS	KAKGQPREPQ	350
VYTLPPSQEE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPPV	400
LDSGGSFFLY	SRLTVDKSRW	QEGNVFSCSV	MHEALHNRFT	QKSLSLSPGK	450

Light chain X'

DIQMTQSPSS	LSASVGDRV	ITCRASQSI	TYLNWYQQK	GKAPKLLIY	50'
ASSLQSGVPS	RFSGSGSGT	FTLTISLQ	EDFATYYCQ	SYSTPPIFG	100'
QGTRLEIKRT	VAAPSVFIF	PSDEQLKSG	ASVVCLLNF	YPREAKVQWK	150'
VDNALQSGNS	QESVTEQDS	DSTYSLSSL	TLKADYEKH	KVYACEVTH	200'
GLSSPVTKSF	NRGEC				215'

Heavy chain X''

QVQLVESGGG	LVKPGGSLRL	SCAASGFTFS	NYYMWSVRQA	PGKGLEWISY	50''
ISGRGSTIFY	ADSVKGRITI	SRDNAKNSLF	LQMNSLRAED	TAVYFCVKDR	100''
GGYSPYWGQG	TLVTVSSAST	KGPSVFPLAP	CSRSTSESTA	ALGCLVKDYF	150''
PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVVTVPS	SSLGTKTYTC	200''
NVDHKPSNTK	VDKRVESKYG	PPCPAP	VAGPSVFLFP	PKPKDTLMIS	250''
RTPEVTCVVV	DVSQEDPEVQ	FNWYVDGVEV	HNAKTKPREE	QFNSTYRVVS	300''
VLTVLHQDWL	NGKEYKCKVS	NKGLPSSIEK	TISKAKGQPR	EPQVYTLPPS	350''
QEEMTKNQVS	LTCLVKGFYP	SDIAVEWESN	GQPENNYKTT	PPVLDSDGSF	400''
FLYSRLTVDK	SRWQEGNVFS	CSVMHEALHN	HYTQKSLSL	LGK	443''

Light chain X'''

DIQMTQSPSS	LSASVGDRV	ITCRASQSI	TYLNWYQQK	GKAPKLLIY	50'''
ASSLQSGVPS	RFSGSGSGT	FTLTISLQ	EDFATYYCQ	SYSTPPIFG	100'''
QGTRLEIKRT	VAAPSVFIF	PSDEQLKSG	ASVVCLLNF	YPREAKVQWK	150'''
VDNALQSGNS	QESVTEQDS	DSTYSLSSL	TLKADYEKH	KVYACEVTH	200'''
GLSSPVTKSF	NRGEC				215'''

Disulfide bridges location

22-96	22''-96''	23'-88'	23'''-88'''	135'-195'	135'''-195'''	131''-215''	138-215'
144''-200''	151-207	223''-230	226''-233	257''-317''	264-324	363''-421''	370-428

Glycosylation sites (N)
Asn-293'' Asn-300

MOLECULAR FORMULA C₆₄₁₄H₉₉₁₇N₁₇₁₁O₂₀₁₆S₄₄ (non glycosylated)

MOLECULAR WEIGHT 144.66 kDa

TRADEMARK None as yet

SPONSOR Regeneron

CODE DESIGNATIONS REGN4018

CAS REGISTRY NUMBER 2305629-50-7

UNII 6BUL1G4D60

WHO NUMBER 11679

gbk